Crinetics Pharmaceuticals, Inc.
(NASDAQ : CRNX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.04%144.600.7%$911.16m
PFEPfizer Inc. -0.72%37.220.9%$778.98m
BMYBristol-Myers Squibb Co. -0.55%60.311.0%$640.84m
MRKMerck & Co., Inc. 0.32%78.520.7%$631.71m
ABBVAbbVie, Inc. -1.37%83.101.9%$582.97m
LLYEli Lilly & Co. -0.98%142.181.1%$495.86m
AZNAstraZeneca Plc 0.29%52.341.2%$201.70m
NVSNovartis AG -1.03%84.810.2%$144.13m
GSKGlaxoSmithKline Plc -0.90%35.720.2%$134.95m
NVONovo Nordisk A/S -0.23%71.090.1%$70.79m
RGENRepligen Corp. 0.49%173.347.1%$63.73m
RPRXRoyalty Pharma Plc -2.72%39.000.2%$57.60m
SNYSanofi -0.76%49.500.2%$48.39m
PRAXPraxis Precision Medicines, Inc. 1.44%28.150.0%$48.08m
AMAGAMAG Pharmaceuticals, Inc. 0.07%13.6522.1%$44.87m

Company Profile

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.